JUL 27 2026
Otsuka Pharmaceutical — SIMTRIYO (centanafadine)
for ADHD
About
SIMTRIYO (centanafadine) is a drug for treating attention deficit hyperactivity disorder (ADHD), a condition that impairs focus and self-control. It works by adjusting the levels of key brain chemicals involved in attention and mood. This dual action may help manage the core symptoms of ADHD, including inattention and impulsivity.
Pivotal trial
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on SIMTRIYO
- FDA approves Simtriyo for treating ADHD in children and adults - Medical Xpress
- FDA approval of Simtriyo gives ADHD prescribers a new option—and new safety questions - MDLinx
- Simtriyo Will Be a Federally Controlled Substance, and Its DEA Schedule Will Shape How Easily Families Can Get It - Medical Daily
- Simtriyo (Centanafadine) for ADHD: How It Works and Side Effects - Everyday Health
- ADHD: FDA Approves New CNS Drug Simtriyo for Adults and Children - healthline.com